Black Diamond Therapeutics Q3 2026 Earnings Date & Estimates

Black Diamond Therapeutics (NASDAQ:BDTX) is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its MasterKey platform to identify cancer-driving mutations and develop small-molecule therapies intended to address mutations across multiple tumor types, rather than focusing exclusively on a single tissue or cancer diagnosis.

Its pipeline has included brain-penetrant targeted therapies designed for patients with oncogenic alterations in pathways such as EGFR and RAF. Among its development programs are BDTX-1535, an investigational EGFR inhibitor being studied in selected solid tumors, and BDTX-4933, an investigational pan-RAF inhibitor intended for cancers driven by MAPK pathway alterations. These programs are being evaluated in clinical studies, and their development status may change as trials progress.

Black Diamond Therapeutics was founded in 2014 and is headquartered in New York. The company serves the global oncology market through drug discovery and clinical development activities, with a focus on treating cancers that may be difficult to address using conventional mutation-specific approaches.